Giants of Cancer Care® Program Inductees
Breast Cancer
Joseph A. Sparano, MD
Chief, Division of Hematology and Medical Oncology
Mount Sinai Health System
Deputy Director
The Tisch Cancer Institute
The Ezra M. Greenspan MD Professorship in Clinical Cancer Therapeutics
Mount Sinai
- Sparano was the principal investigator for the TAILORx trial (NCT00310180), which demonstrated that most women with early breast cancer and a midrange 21-gene recurrence score do not require chemotherapy.
- He also led the phase 3 E1199 trial (NCT00004125), which showed that adjuvant weekly paclitaxel improves overall survival in stage II to III breast cancer. • He developed the rituximab (Rituxan) plus etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) regimen for the management of HIV-associated lymphoma and cetuximab plus cisplatin/5-fluorouracil/radiation for anal cancer.
- Sparano organized an international team to perform a meta-analysis of HIV-lymphoma trials and develop a new prognostic score for HIV-associated lymphoma.
- He played a key role in validating and/or refining prognostic gene expression signatures, including the Oncotype Recurrence Score and DCIS Score, in early-stage breast cancer
- He is the chair and principal investigator of the AIDS Malignancy Consortium, a network of clinical trial sites in the United States, Africa, and Latin America. He also serves as deputy chair of the ECOG-ACRIN Cancer Research Group and is a member of the Board of Managers of the PreECOG Research Foundation and the Early Breast Cancer Trialists’ Collaborative Group Steering Committee.
Home
SUPPORTED BY
